gaap:NonUsMember
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2022-01-03
2023-01-01
0000200406
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2024-01-01
2024-12-29
0000200406
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2023-01-02
2023-12-31
0000200406
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2022-01-03
2023-01-01
0000200406
country:US
jnj:COVID19Member
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2024-01-01
2024-12-29
0000200406
country:US
jnj:COVID19Member
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2023-01-02
2023-12-31
0000200406
country:US
jnj:COVID19Member
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2022-01-03
2023-01-01
0000200406
us-gaap:NonUsMember
jnj:COVID19Member
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2024-01-01
2024-12-29
0000200406
us-gaap:NonUsMember
jnj:COVID19Member
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2023-01-02
2023-12-31
0000200406
us-gaap:NonUsMember
jnj:COVID19Member
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2022-01-03
2023-01-01
0000200406
jnj:COVID19Member
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2024-01-01
2024-12-29
0000200406
jnj:COVID19Member
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2023-01-02
2023-12-31
0000200406
jnj:COVID19Member
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2022-01-03
2023-01-01
0000200406
country:US
jnj:EDURANTrilpivirineMember
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2024-01-01
2024-12-29
0000200406
country:US
jnj:EDURANTrilpivirineMember
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2023-01-02
2023-12-31
0000200406
country:US
jnj:EDURANTrilpivirineMember
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2022-01-03
2023-01-01
0000200406
us-gaap:NonUsMember
jnj:EDURANTrilpivirineMember
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2024-01-01
2024-12-29
0000200406
us-gaap:NonUsMember
jnj:EDURANTrilpivirineMember
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2023-01-02
2023-12-31
0000200406
us-gaap:NonUsMember
jnj:EDURANTrilpivirineMember
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2022-01-03
2023-01-01
0000200406
jnj:EDURANTrilpivirineMember
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2024-01-01
2024-12-29
0000200406
jnj:EDURANTrilpivirineMember
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2023-01-02
2023-12-31
0000200406
jnj:EDURANTrilpivirineMember
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2022-01-03
2023-01-01
0000200406
country:US
jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2024-01-01
2024-12-29
0000200406
country:US
jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
jnj:InnovativeMedicineMember
jnj:InfectiousDiseasesMember
2023-01-02
2023-12-31
0000200406
country:US
jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
jnj:InnovativeMedicineMember